Peptid-Klartext DE Community
Growth hormone

CJC-1295: Effects, Evidence and Risks

Also known as CJC-1295 with or without “DAC”.

StatusNot approved
EvidenceSmall human studies
Drug classGHRH analogue (growth hormone-releasing hormone)

What is CJC-1295?

Stimulates the pituitary gland to release more of the body's own growth hormone. The “DAC” version binds to albumin and therefore acts for days.

How well studied is CJC-1295?

Early human studies (2006) showed a clear, sustained rise in GH and IGF-1. Clinical development was discontinued afterwards.

What side effects and risks does CJC-1295 have?

Water retention, tingling, flushing, possible effects on blood sugar. Persistently elevated IGF-1 is a debated risk factor. No long-term data.

Is CJC-1295 approved in Germany?

In short: no. Not approved. Banned in sport (WADA S2).

Sources

Note: We deliberately do not list any doses here. For approved medicines, your doctor sets the dose; for unapproved substances there is no reliable information.